Concomitant radiochemotherapy with temozolomide in non-selected patients with newly diagnosed high-grade gliomas

Anticancer Research

Volumn 26, Issue 6 C, 2006, Pages 4959-4964

  Eberlein, Klaus H ^a   Nagel, Britta ^a   Franz, Kea ^a   Imhoff, Detlef ^a   Seifert, Volker ^a   Boettcher, Heinz D ^a   Mose, Stephan ^b  

^a GOETHE UNIVERSITY   (Germany)

^b Villingen Schwenningen Hospital   (Germany)

Author keywords

Glioblastoma multiforme; High grade glioma; Malignant glioma; Radiochemotherapy; Survival; Temozolomide

Indexed keywords

ANTIEMETIC AGENT; TEMOZOLOMIDE;

ADULT; AGED; ANEMIA; ARTICLE; BLOATING; CANCER GRADING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKOPENIA; MAJOR CLINICAL STUDY; NAUSEA; PRIORITY JOURNAL; THROMBOCYTOPENIA; TUMOR BIOPSY;

ADULT; AGED; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; GLIOMA; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 33845915295     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Anders K, Grabenbauer GG, Schuchardt U, Fahlbusch R, Fietkau R, Sauer R and Krauseneck P: Accelerated radiotherapy with concomitant ACNU/Ara-C for the treatment of malignant glioma. J Neurooncol 48: 63-73, 2000.
2. Bamberg M, Budach V, Stuschke M and Gerhard L: Preliminary experimental results with the nitrosourea derivative ACNU in the treatment of malignant gliomas. Radiother Oncol 12: 25-29, 1988.
3. Brandes AA, Rigon A, Zampieri P, Ermani M, Carollo C, Altavilla G, Turazzi S, Chierichetti F and Fiorentino MW: Carboplatin and teniposide concurrent with radiotherapy in - patients with glioblastoma multiforme: a phase II study. Cancer 82: 355-361, 1998.
4. Brandes AA, Rigon A, Zampieri P, Scelzi E, Amista P, Berti F, Rotilio A, Gardiman M and Florentino MV: Early chemotherapy and concurrent radio-chemotherapy in high grade glioma. J Neurooncol 30: 247-255, 1996.
5. Buckner JC, Schomberg PJ, McGinnis WL, Cascino TL, Scheithauer BW, O'Fallon JR, Morton RF, Kuross S-A, Mailliard JA, Hatfield AK, Cole JT, Steen PD and Bernath AM: A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma. Cancer 12: 2013-2021, 1994.
6. Chamberlain MC and Kormanik P: Salvage chemotherapy with paclitaxel for recurrent primary brain tumors. J Clin Oncol 13: 2066-2071, 1995.
7. Dinapoli RP, Brown LD, Arusell R-M, Earle JD, O'Fallon JR, Buckner JC, Scheithauer BW, Krook JE, Tschetter LK and Maier JA: Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma. J Clin Oncol 11: 1316-1321, 1993.
8. Fernandez Hidalgo OA, Vanaclocha V, Vieitez JM, Aristu JJ, Rebollo J, Gurpide A, Aramendia JM, Moreno Palanques R, Martin Algarra S, Subira ML and Brugarolas A: High-dose BCNU and autologous progenitor cell transplantation given with intra-arterial cisplatinum and simultaneous radiotherapy in the treatment of high-grade gliomas: benefit for selected patients. Bone Marrow Transplant 18: 143-149, 1996.
9. Fetell MR, Grossman SA, Fisher JD, Erlanger B, Rowinsky E, Stockel J and Piantadosi S: Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium. J Clin Oncol 15: 3121-3128, 1997.
10. Feun LG, Stewart DJ, Maor M, Leavens M, Savaraj N, Burgess MA, Yung WK and Benjamin RS: A pilot study of cis-diamminedichloroplatinum and radiation therapy in patients with high grade astrocytomas. J Neurooncol 1: 109-113, 1983.
11. Fisher BJ, Scott C, Macdonald DR, Coughlin C and Curran WJ: Phase I study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group Trial 9507. J Clin Oncol 19: 1111-1117, 2001.
12. Fountzilas G, Karavelis A, Capizzello A, Kalogera Fountzilas A, Karkavelas G, Zamboglou N, Selviaridis P, Foroglou G and Tourkantonis A: Radiation and concomitant weekly administration of paclitaxel in patients with glioblastoma multiforme. A phase II study. J Neurooncol 45: 159-165, 1999.
13. Grabenbauer GG, Anders K, Buchfelder M, Staab H-J and Sauer R: Topotecan als 21-Tage-Dauerinfusion mit akzelerierter 3-D-Konformationsbestrahlung. Strahlenther Onkol 175: 195, 1999 (abstract).
14. Grossman SA, Wharam M, Sheidler V, Kleinberg L, Zeltzman M, Yue N and Piantadosi S: Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma. J Clin Oncol 15: 2596-2603, 1997.
15. Groves MD, Maor MH, Meyers C, Kyritsis AP, Jaeckle KA, Yung WK, Sawaya RE, Hess K, Bruner JM, Peterson P and Levin VA: A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme. Int J Radiat Oncol Biol Phys 45: 127-135, 1999.
16. Gruber ML, Glass J, Choudhri H and Nirenberg A: Carboplatin chemotherapy before irradiation in newly diagnosed glioblastoma multiforme. Am J Clin Oncol 21: 338-340, 1998.
17. Iwadate Y, Namba H and Sueyoshi K: Intra-arterial ACNU and cisplatin chemotherapy for the treatment of glioblastoma multiforme. Neurol Med Chir 35: 598-603, 1995.
18. Jeremic B, Jovanovic D, Djuric LJ, Jevremovic S and Mijatovic LJ: Advantage of post-radiotherapy chemotherapy with CCNU, procarbazine, and vincristine (mPCV) over chemotherapy with VM-26 and CCNU for malignant gliomas. J Chemother 4: 123-126, 1992.
19. Julka PK, Awasthy BS, Rath GK, Agarwal S, Varna T, Mahapatra AK and Singh R: A study of concurrent radiochemotherapy with paclitaxel in glioblastoma multiforme. Australas Radiol 44: 84-87, 2000.
20. Kim L, Hochberg FH, Thornton AF, Harsh GR, Patel H, Finkelstein D and Louis DN: Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J Neurooncol 85: 602-607, 1996.
21. Klautke G, Hamann D, Bahner T, Zettl U and Fietkau R: Simultane Radio- / Chemotherapie mit Topotecan bei Glioblastomen. Strahlenther. Onkol 175: 191,1999 (abstract).
22. Lassen U, Kristjansen PE, Wagner A, Kosteljanetz M and Poulsen HS: Treatment of newly diagnosed glioblastoma multiforme with carmustine, cisplatin and etoposide followed by radiotherapy. A phase II study. J Neurooncol 43: 161-166, 1999.
23. Levin VA, Prados MR, Wara WM, Davis RL, Gutin PH, Phillips TL, Lamborn K and Wilson CB: Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas. Int J Radiat Oncol Biol Phys 32: 75-83, 1995.
24. Levin VA, Silver P, Hannigan J, Wara WM, Gutin PH, Davis RL and Wilson CB: Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas. NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 18: 321-324, 1990.
25. A Medical Research Council Trial. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma. J Clin Oncol 19: 509-518, 2001.
26. Prados MD, Scott C, Curran WJ, Nelson DF, Leibel S and Kramer S: Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: a retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy. J Clin Oncol 17: 3389-3395, 1999.
27. Prados MD, Scott C, Sandier H, Buckner JC, Phillips T, Schultz C, Urtasun R, Davis R, Gutin P, Cascino TL, Greenberg H-S and Curran WJ: A phase III randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: a preliminary report of RTOG 9404. Int J Radiat Oncol Biol Phys 45: 1109-1115, 1999.
28. Rajkumar SV, Buckner JC, Schomberg PJ, Cascino TL, Burch PA and Dinapoli RP: Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma. Int J Radiat Oncol Biol Phys 40: 297-302, 1998.
29. Rajkumar SV, Buckner JC, Schomberg PJ, Reid JM, Bagniewski PJ, Ames MM, Cascino TL and Marks RS: Phase I and pharmacokinetic study of preirradiation chemotherapy with BCNU, cisplatin, etoposide, and accelerated radiation therapy in patients with high-grade glioma. Int J Radiat Oncol Biol Phys 42: 969-975, 1998.
30. Stewart DJ, Dahrouge S, Agboola O and Girard A: Cranial radiation and concomitant cisplatin and mitomycin-C plus resistance modulators for malignant gliomas. J Neurooncol 32: 161-168, 1997.
31. Bamberg M and Hess CF: Radiation therapy for malignant glioma. Onkologie 15: 178-189, 1992.
32. Curran WJ, Scott CB, Nelson JS, Weinstein AS, Phillips TL, Murray K, Fischbach AJ, Yakar D, Schwade JG and Powlis WD: A randomized trial of accelerated hyperfractionated radiation therapy and bis-chloroethyl nitrosourea for malignant glioma. A preliminary report of Radiation Therapy Oncology Group 83-02. Cancer 70: 2909-2917, 1992.
33. Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM and Yung WK: Phase II trial of the antiangiogenetic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18: 708-715, 2000.
34. Jeremic B, Grujicic D, Antunovic V, Djuric L and Shibamoto Y: Accelerated hyperfractionated radiation therapy for malignant glioma. A phase II study. Am J Clin Oncol 18: 449-453, 1995.
35. Nelson DF, Curran WJ, Scott C, Nelson JS, Weinstein AS, Ahmad K, Constine LS, Murray K, Powlis WD and Mohiuddin M: Hyperfractionated radiation therapy and bis-chloroethyl nitrosourea in the treatment of malignant glioma - possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302. Int. J Radiat Oncol Biol Phys 25: 193-207, 1993.
36. 6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16: 3851-3857, 1998.
37. Ostermann S, Csajka C, Buclin T, Leyvraz S, Lejeune F, Decosterd LA and Stupp R: Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin. Cancer Res 10: 3728-3736, 2004.
38. Brada M, Judson I, Beale P, Moore S, Reidenberg P, Statkevich P, Dugan M, Batra V and Cutler D: Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH-52365) for refractory or relapsing malignancies. Br J Cancer 81: 1022-1030, 1999.
39. Yung WKA, Prados MD, Yaga-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O'Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S and Levin VA: Multicenter Phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17: 2762-2771, 1999.
40. 6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88: 1004-1011, 2003.
41. Curtin NJ, Wang LZ, Yiakouvaki A, Kyle S, Arris CA, Canan-Koch S, Webber SE, Durkacz BW, Calvert HA, Hostomsky Z and Newell DR: Novel poly (ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells. Clin. Cancer Res 10: 881-889, 2004.
42. Trivedi RN, Almeida KH, Fornsaglio JL, Schamus S and Sobol RW: The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. Cancer Res 65: 6394-6400, 2005.
43. Stupp R, Dietrich PY, Ostermann S, Kraljevic S, Pica A, Maillard I, Maeder P, Meuli R, Janzer R, Pizzolato G, Miralbell R, Porchet F, Regli L, de Tribolet N, Mirimanoff RO and Leyvraz S: Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20: 1375-1382, 2002.
44. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross G, Eisenhauer E, Mirimanoff RO for the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor and Radiotherapy Groups and National Cancer Institute of Canada Clinical Trial Group (NCIC CTG): Radiotherapy plus concomitant and adjuvant temozolomide for patients with newly diagnosed glioblastoma. N Engl J Med 352: 987-996, 2005.
45. Hess CF, Kortmann RD, Schabet M and Bamberg M: Malignant glioma: patterns of failure following individually tailored limited volume irradiation. Radiother Oncol 30: 146-149, 1994.
46. Alheit H, Dornfeld S, Dawel M, Alheit M, Henzel B, Steckler K, Blank H and Geyer P: Patient position reproducibility in fractionated stereotactically guided conformal radiotherapy using the BrainLab mask system. Strahlenther. Onkol 177: 264-268, 2001.
47. Jeremic B, Shibamoto Y, Grujicic D, Milicic B, Stojanovic M, Nikolic N, Dagovic A and Aleksandrovic J: Pre-irradiation carboplatin and etoposide and accelerated hyperfractionated radiation therapy in patients with high-grade astrocytomas: a phase II study. Radiother Oncol 51: 27-33, 1999.
48. Jeremic B, Shibamoto Y, Grujicic D, Stojanovic M, Milicic B, Nikolic N, Dagovic A and Aleksandrovic J: Concurrent accelerated hyperfractionated radiation therapy and carboplatin/etoposide in patients with malignant glioma: long term results of a phase II study. J Neurooncol 51: 133-141, 2001.
49. Werner Wasik M, Scott CB, Nelson DF, Gaspar LE, Murray KJ, Fischbach AJ, Nelson JS, Weinstein AS and Curran WJ: Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group 83-02. Cancer 77: 1535-1543, 1996.
50. Ganju V, Jenkins RB, O'Fallon JR, Scheithauer BW, Ransom DT, Katzmann JA and Kimmel DW: Prognostic factors in gliomas. Cancer 74: 920-927, 1994.
51. Miller PJ, Hassanein RS and Shankar PG: Univariante and multivariante statistical analysis of high-grade gliomas: The relationship of radiation dose and other prognostic factors. Int J Radiat Oncol Biol Phys 19: 275-280, 1990.